Piracetam, 400 mg capsules, 20 pcs.

Piracetam activates associative processes in the central nervous system, improves mood, memory and mentality in sick and healthy people. It stimulates intellectual activity and integrative activity of the brain, facilitates learning processes, improves connections between hemispheres of the brain and synaptic conduction in the cortex, increases mental performance, stabilizes and restores impaired brain functions (memory, consciousness, speech). Piracetam normalizes the ratio of ADP and ATP (inhibits nucleotide phosphatase and activates adenylate cyclase), increases phospholipase A activity, stimulates bioenergetic and plastic processes in nervous tissue, and accelerates neurotransmitter exchange.

Piracetam increases resistance of brain tissue to toxic influences and hypoxia, increases the synthesis of phospholipids and nuclear RNA, and increases glycolytic processes and glucose utilization in the brain. Piracetam blocks platelet aggregation, improves microcirculation, optimizes the ability of red blood cells to pass through microvessels and the conformational properties of the red blood cell membrane, increases regional blood flow in ischemic brain areas. Piracetam increases EEG beta and alpha activity and decreases delta activity. It reduces vestibular nystagmus. During hypoxia, intoxication, trauma, electroconvulsive effect has a neuroprotective effect.

In connection with antihypoxic action piracetam is effective in complex treatment of myocardial infarction. Anxiolytic and sedative effects of piracetam are absent.

Piracetam is almost completely and quickly absorbed after oral administration. Bioavailability is 100%. When oral administration of 2 g of the drug the maximum concentration in plasma is 40-60 mcg/ml after 30 minutes. Piracetam does not bind to plasma proteins. After 2-8 hours the maximum concentration in the cerebrospinal fluid is reached. Piracetam penetrates all tissues and organs, penetrates through the placental barrier. It is almost not metabolized. It accumulates selectively in cerebral cortex, mainly in parietal, frontal and occipital lobes, basal ganglia and cerebellum. Half-life of piracetam from plasma is 4-5 hours; from cerebrospinal fluid it is 6-8 hours. More than 95% of the drug is excreted unchanged by the kidneys after 30 hours. The elimination half-life is longer in patients with renal insufficiency.

Indications

Hangover, Learning Disabilities, Dizziness, Mental Retardation in Children, Alcoholism, Cerebral Circulatory Disorder, Stroke Consequences, Concussion and Other Brain Injuries, Headache, Tinnitus, Attention and Memory Impairment

• Cronic Cerebrovascular Insufficiency (hypertension, atherosclerosis, vascular Parkinsonism, which is accompanied by impaired attention, memory and speech.Chronic cerebrovascular insufficiency (hypertension, atherosclerosis, vascular parkinsonism), which is accompanied by impaired attention, memory, speech, headache and dizziness;
• ischemic stroke and its consequences;
• psychorganic disorders;
• dementia (senile dementia, Alzheimer’s disease, vascular dementia);
• cranial trauma;
• intoxication (recovery period, comatose and subcomatose states);
• diseases of the nervous system, which are accompanied by a decrease in the level of awakeness, intellectual and mental functions, behavioral and emotional-volitional disorders;
• dizziness;
• vestibular nystagmus;
• painful-apathetic state;
• aphasia;
• Epilepsy (as an adjuvant);
• senile and atrophic processes;
• depressive conditions that are resistant to antidepressant treatment;
• Prevention or elimination of neurological, somatovegetative, psychiatric complications of neuroleptic and other psychotropic drugs treatment;
• neurotic depression with prevalence in the clinical picture of senesto-psychondriacal and asthenic disorders, adynamia, ideomotor retardation phenomena;
• depression with prevalence ofPsycho-organic syndrome in chronic alcoholism;
• curing the pre- and delirium, withdrawal states in drug addiction and alcoholism;
• acute intoxication with morphine, ethanol, amphetamines, barbiturates;
• children – cerebral palsyIn children – cerebral palsy, consequences of perinatal damage of the central nervous system, mental retardation, learning disability in psychoorganic syndrome, speech disorder, oligophrenia, memory impairment, cerebristia, intellectual failure;
• Severine cell anemia (as a part of complex treatment).

.

Active ingredient

Piracetam

Composition

Active substance:

Piracetam 400 mg;

Associates:

Silicon dioxide colloid – 3 mg;

Capsule cap:

gelatin – 24.395 mg;

methylparahydroxybenzoate – 0.236 mg;

propyl parahydroxybenzoate – 0.059 mg;

sodium lauryl sulfate – 0.023 mg;

Sunset Yellow dye – 0.0861 mg;

Punsen dye (Ponceau 4R) – 0.2118 mg;

Brilliant blue dye – 0.2112 mg

Capsule shell:

gelatin, 39.68 mg; methyl parahydroxybenzoate, 0.384 mg; propyl parahydroxybenzoate, 0.106 mg;